Norbert Bischofberger, Kronos Bio CEO

Kro­nos and Genen­tech ink $20M can­cer dis­cov­ery pact

Kro­nos Bio and Roche’s Genen­tech an­nounced a drug dis­cov­ery deal to hunt for and de­vel­op small mol­e­cule drugs aimed at tran­scrip­tion fac­tors that can dri­ve …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.